Eupraxia Pharmaceuticals Inc. (EPRX)
(Delayed Data from NSDQ)
$5.42 USD
+0.06 (1.14%)
Updated Aug 6, 2025 03:59 PM ET
After-Market: $5.39 -0.03 (-0.55%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
EPRX 5.42 +0.06(1.14%)
Will EPRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for EPRX
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Analyst Coverage Initiated on EPRX with Overweight Rating | EPRX Stock News
Cantor Fitzgerald Assigns Overweight Rating to EPRX with $11 Price Target | EPRX Stock News
Eupraxia Pharmaceuticals initiated with bullish view at Cantor Fitzgerald
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences | EPRX Stock News